Health authorities now advise that aspirin is no longer recommended for routine prevention of cardiovascular events in many adults. Updated guidance reflects new evidence about bleeding risks and limited benefits for people without a history of heart disease.
This change affects primary care practice, patient discussions, and pharmacy recommendations as clinicians reassess who might still benefit from daily low-dose aspirin.
| Guideline Body | Recommendation Status | Key Population | Considerations |
|---|---|---|---|
| American Heart Association / American College of Cardiology (2019) | Not routinely recommended for primary prevention in adults 70+ or at increased bleeding risk | Older adults, adults on anticoagulants | Individualized decision-making emphasized |
| U.S. Preventive Services Task Force (2022 draft) | D recommends initiating daily aspirin for CVD prevention in adults 60–69 | Adults 60–69 without prior CVD | Net benefit is small and bleeding risk is notable |
| European Society of Cardiology (2024 update) | Aspirin generally not recommended for primary prevention in low-risk individuals | Low-risk adults | Focus on lifestyle and risk factor control |
| Task Force on Practice Guidelines (2022) | Selective use in select higher-risk adults after shared decision-making | Selected higher-risk adults | Bleeding risk must be weighed against potential benefit |
Risk Of Bleeding Outweighs Preventive Benefit
Gastrointestinal And Intracerebral Concerns
Daily aspirin increases the risk of gastrointestinal bleeding and intracerebral hemorrhage, especially in older adults. These harms are more common in people with prior peptic ulcers, concurrent anticoagulants, or uncontrolled hypertension.
Age Specific Risk Patterns
As people age, baseline bleeding risk rises while the expected cardiovascular benefit from aspirin for primary prevention declines. This shift makes routine use less favorable for adults over 70, even when overall cardiovascular risk appears moderate.
Guideline Updates Driving The Change
Evidence Review And Policy Shift
Recent systematic reviews and large trials showed that aspirin reduced major cardiovascular events only modestly in primary prevention. In response, multiple guideline committees moved from selective to nonrecommendation for most adults, emphasizing shared decision-making when benefit still appears plausible.
Clinical Considerations For People Previously On Aspirin
Discontinuation And Decision Pathways
For adults whose prior use was for primary prevention, clinicians often pause rather than restart aspirin during routine care. Decisions to restart depend on individual factors such as recent vascular events, overall life expectancy, and patient values about small potential benefit versus bleeding risk.
Shared Decision-Making For Risk And Benefit
Identifying Candidates Who May Still Benefit
Select patients with higher estimated atherosclerotic cardiovascular disease risk, lower bleeding risk, and life expectancy of at least several years might still be candidates after careful discussion. Factors such as diabetes, smoking, and kidney function refine personalized risk assessment but do not automatically justify routine aspirin use.
Key Takeaways For Patients And Clinicians
- Aspirin is no longer routinely recommended for primary cardiovascular prevention in many adults, especially older patients and those at higher bleeding risk.
- Guideline shifts reflect new evidence showing limited net benefit when bleeding risks are included.
- People with a history of heart attack, stroke, or certain stents usually remain on aspirin for secondary prevention.
- Shared decision-making is central; clinicians should discuss individual risks, benefits, and preferences before starting or continuing aspirin.
- Review current aspirin use periodically with your clinician, especially during medication changes, surgery planning, or new health conditions.
FAQ
Reader questions
Should I stop taking aspirin if my doctor previously recommended it for heart prevention?
Do not stop or change aspirin without talking to your clinician. They will review your bleeding risk, cardiovascular history, age, and other medications to decide whether continuing daily aspirin is appropriate for you.
Are there situations where aspirin is still strongly recommended despite the new guidance?
Yes, people with a history of heart attack, stroke, or certain types of stents generally still require aspirin for secondary prevention. The updated guidance mainly affects adults without prior cardiovascular disease who are considering starting aspirin.
Does this change apply to low-dose aspirin used for pain or inflammation?
These recommendations focus on low-dose aspirin used specifically for cardiovascular prevention. Short-term use for pain or fever at standard doses is typically unaffected, but long-term use should also be discussed with a clinician.
What should I do if I am already taking aspirin and have upcoming surgery?
Tell your surgeon and anesthesiologist about daily aspirin so they can advise on temporary discontinuation. Decisions balance bleeding risk during the procedure against the need to prevent blood clots, and they should be made jointly with your care team.